Research Projects

The objective of this project is to develop a business plan for the continued clinical development and commercialisation of ALZ-101 – a novel therapeutic Alzheimer´s disease (AD) vaccine candidate designed to prevent neurodegeneration in the brain. AD is a therapeutic area in dire need of effective treatments. The disease, which primarily afflicts...

Protein aggregation hallmarks several neurodegenerative diseases, including Alzheimer's and Parkinson's. In Parkinson's, aggregation of the intrinsically disordered protein (IDP) alpha-synuclein (Syn) leads to its intracellular deposition into Lewy bodies, which causes neuronal dysfunction. Recently it was discovered that Syn can undergo liquid...

There is great need to develop safer and more biologically relevant models for drug screening. Recent reports indicate that up to 20% of acute kidney complications can be linked to drug-induced nephrotoxicity and more than 40 molecules found to reduce Alzheimer’s Disease (AD)-related plaques in animal models were shown to be ineffective in AD...

Brain disorders impose an increasing economical and social burden in the member states of the European Union (EU). For most neurodegenerative diseases and many neuropsychiatric disorders no efficient treatment is available and no cure exists. In the next coming years the number of particularly elderly people suffering from brain disorders will...

This IRG will support my return to the EU as a Senior Lecturer in Nutrition and Neuroscience at the Hebrew University of Jerusalem, bringing state-of-the-art science and technology, collaborations, and excellent prospects for reintegration and the enhancement of European competitiveness. My research aims to elucidate the metabolic basis of brain...

Dementia is an umbrella term for age-related brain disease, of which Alzheimer’s Disease (AD) is the most common. Around 5-7% of adults over 60 years suffer dementia worldwide, with approx. 8.7 m people in the EU. A frequent precursor of AD is amnestic mild cognitive impairment (aMCI), a clinical condition characterised by declines in memory skills...

At present more than 5 million people in the EU suffer from dementia and other neurodegenerative diseases and that number will grow as the average age of the population continues to increase. The efficacy of current medicines is limited and new therapeutic targets are sorely needed. Several independent lines of evidence have established an...

Novel diagnostic techniques and disease models have the powerful potential to provide new insights into pathological and pathophysiological processes. Ocular manifestations of Alzheimer’s disease (AD) emerge as novel and attractive alternative to investigate disease progression in parallel to the brain. Using the eye as a window to the brain, we...

Loss of vision is frequently related to disorders of the retina that may be either primary or secondary such as involvement in metabolic or neurologic disorders. Since the retina constitutes an easily accessible outpost of the brain, it emerged as top research target for non-invasive diagnostics of neurological diseases such as Alzheimers disease...

Alzheimer’s disease (AD) heterogeneity is associated with distinct risk factors, clinical manifestations, rates of cognitive decline, and comorbidities. However, this population variance is not properly incorporated in clinical trial design, directly hampering successful development of treatments. As the field is shifting towards (early) secondary...

A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Parkinson’s disease (PD) is associated with tremor and loss of motor functions due to progressive degeneration of dopaminergic neurons in the brain. This can lead to memory loss and dementia, which is associated...

The aim of this proposal is to submit proposal for two presidency conferences organized under the auspices of the Slovakian Presidency to the Council of the European Union.